Search results for "From ACP Journal Club"
Adding lisinopril to losartan increased hyperkalemia and acute kidney injury in type 2 diabetes and proteinuria
In a trial of more than 1,000 diabetic patients with proteinuria, adding an ACE inhibitor to an ARB didn't improve estimated glomerular filtration rate and increased risk for hyperkalemia and acute kidney injury, so the trial was halted early.
https://diabetes.acponline.org/archives/2014/05/09/6.htm
9 May 2014
In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes
The data suggest that renoprotection from sodium-glucose cotransporter-2 (SGLT-2) inhibitors may not require the presence of diabetes or albuminuria and may be effective even in patients with worse renal function, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2020/03/13/6.htm
13 Mar 2020
SGLT-2 inhibitors were not linked to severe or nonsevere UTIs vs DPP-4 inhibitors or GLP-1 agonists
An ACP Journal Club commentary called the results of this real-world, retrospective study reassuring regarding concerns about associations of urinary tract infections (UTIs) with sodium-glucose cotransporter-2 (SGLT-2) inhibitors.
https://diabetes.acponline.org/archives/2020/01/10/8.htm
10 Jan 2020
In acute ischemic stroke with hyperglycemia, intensive vs standard glucose control did not improve 90-day outcomes
Several factors, including high rates of reperfusion therapy and early hospital discharge, may explain why this trial found no benefit from intensive glucose control after stroke, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/01/10/7.htm
10 Jan 2020
In newly diagnosed type 2 diabetes mellitus, a Mediterranean diet (vs. a low-fat diet) delayed start of glucose-lowering drugs
Patients who were randomized to a low-carbohydrate Mediterranean diet shortly after type 2 diabetes diagnosis delayed their need for medication compared to those put on a low-fat diet in an Italian trial.
https://diabetes.acponline.org/archives/2014/10/10/5.htm
10 Oct 2014
Review: In type 2 diabetes, sodium–glucose cotransporter 2 inhibitors do not increase major CV events or mortality
The meta-analysis included 37 trials that compared canagliflozin, dapagliflozin, or empagliflozin to placebo or other active antidiabetic treatments.
https://diabetes.acponline.org/archives/2017/02/10/6.htm
10 Feb 2017
Dapagliflozin reduced cardiorenal outcomes but not MACE in T2 diabetes with or at risk for atherosclerotic CVD
Baseline kidney disease, albuminuria, and cardiovascular disease (CVD) status may help determine which patients will benefit most from sodium-glucose cotransporter-2 inhibitors, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/11/08/7.htm
8 Nov 2019
Continuous glucose monitoring reduced hypoglycemia over 6 months
The positive results of a trial of continuous glucose monitoring in type 1 diabetes patients ages 60 years and older support recommending the technology to this group, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/12/11/10.htm
11 Dec 2020
Canagliflozin reduced kidney failure and CV events at 2.6 years in type 2 diabetes with chronic kidney disease
Sodium–glucose cotransporter 2 inhibitors appear to be a promising treatment option for patients with diabetes and chronic kidney disease, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/09/13/6.htm
13 Sep 2019
Incretin use was not associated with increased risk for acute pancreatitis
Patients who took incretin-based drugs had the same risk of acute pancreatitis as those who took other hypoglycemic medications or took neither type of drug, a case-control study found.
https://diabetes.acponline.org/archives/2015/07/10/6.htm
10 Jul 2015